Analysis Tools
integument
blistering
(
J:261781
)
|
• skin blisters of anti-Col17a1 NC16A autoantibody injected mice are subepidermal, lesional site is at the lamina lucida, and the skin contains degranulated dermal mast cells and a predominant neutrophil infiltrate but no eosinophils
• mice pretreated with cobra venom factor to deplete complement are resistant to the pathogenic effects of the anti-Col17a1 NC16A autoantibodies
• mice pretreated with cromolyn, an inhibitor of mast cell activation, show inhibition of anti- anti-Col17a1 NC16A autoantibody-induced mast cell degranulation, neutrophil infiltration and blistering
• mice pretreated with neutrophil-depleting rat antibody show inhibition of anti-Col17a1 NC16A autoantibody-induced neutrophil infiltration and bullous pemphigoid
|
skin lesions
(
J:261781
)
|
• neonatal mice injected with anti-Col17a1 NC16A autoantibodies develop skin lesions at 24 hours past-injection containing deposition of human IgG and murine C3 at the basement membrane zone indicative of bullous pemphigoid
|
immune system
|
• skin lesions/blisters of anti-Col17a1 NC16A autoantibody injected mice contain degranulated dermal mast cells
|
|
• skin lesions/blisters of anti-Col17a1 NC16A autoantibody injected mice contain a predominant neutrophil infiltrate but no eosinophils
|
hematopoietic system
|
• skin lesions/blisters of anti-Col17a1 NC16A autoantibody injected mice contain degranulated dermal mast cells
|
|
• skin lesions/blisters of anti-Col17a1 NC16A autoantibody injected mice contain a predominant neutrophil infiltrate but no eosinophils
|
cellular
|
• skin lesions/blisters of anti-Col17a1 NC16A autoantibody injected mice contain degranulated dermal mast cells
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| bullous pemphigoid | DOID:8506 | J:261781 | ||
